July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
2 citations
,
December 1994 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
16 citations
,
November 2018 in “The journal of pain/Journal of pain” 14,15-EET may help reduce poststroke pain by affecting certain brain proteins.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
3 citations
,
August 2022 in “International Journal of Molecular Sciences” TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
Individualized treatments may help manage Dercum's disease symptoms.
5 citations
,
July 2024 in “Archives of Dermatological Research” 3 citations
,
July 2025 in “International Immunopharmacology” May 2024 in “Reactions weekly” 45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
January 2026 in “SSRN Electronic Journal” 3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
20 citations
,
September 1983 in “Archives of dermatology” The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.